JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol.321, no.2, pp.175-187, 2019 (SCI-Expanded)
IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressiveMS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition.